Tags

Type your tag names separated by a space and hit enter

Comparison of efficacy of moxidectin and ivermectin in the treatment of Strongyloides fulleborni infection in rhesus macaques.
J Med Primatol. 2006 Jun; 35(3):172-6.JM

Abstract

BACKGROUND

Strongyloides infection may result in clinical disease or confound experimental protocols that utilize non-human primates. There is presently a Strongyloides fulleborni infection rate of approximately 27% in the Tulane National Primate Research Center's breeding colonies despite the routine therapeutic and prophylactic use of ivermectin.

METHODS

A study was conducted to determine if moxidectin treatment offers advantages to the intestinal parasite control program. A total of 150 rhesus macaques (Macaca mulatta) that were removed from the breeding colonies due to illness were selected for the study. The animals were randomly assigned to treatment groups with 75 receiving ivermectin and 75 receiving moxidectin. Egg counts were performed on fecal samples collected pre- and post-treatment.

RESULTS

Both treatments resulted in decreases in the number of eggs/g in the post-treatment sample as compared with the pre-treatment sample; however, no significant difference was found between treatment groups.

CONCLUSIONS

With the data demonstrating a similar efficacy in both ivermectin and moxidectin treated macaques, the benefit of moxidectin treatment relates to biosafety and topical application.

Authors+Show Affiliations

Division of Veterinary Medicine, Tulane National Primate Research Center, Covington, LA 70433, USA. jdufour@tulane.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16764676

Citation

Dufour, Jason P., et al. "Comparison of Efficacy of Moxidectin and Ivermectin in the Treatment of Strongyloides Fulleborni Infection in Rhesus Macaques." Journal of Medical Primatology, vol. 35, no. 3, 2006, pp. 172-6.
Dufour JP, Cogswell FB, Phillippi-Falkenstein KM, et al. Comparison of efficacy of moxidectin and ivermectin in the treatment of Strongyloides fulleborni infection in rhesus macaques. J Med Primatol. 2006;35(3):172-6.
Dufour, J. P., Cogswell, F. B., Phillippi-Falkenstein, K. M., & Bohm, R. P. (2006). Comparison of efficacy of moxidectin and ivermectin in the treatment of Strongyloides fulleborni infection in rhesus macaques. Journal of Medical Primatology, 35(3), 172-6.
Dufour JP, et al. Comparison of Efficacy of Moxidectin and Ivermectin in the Treatment of Strongyloides Fulleborni Infection in Rhesus Macaques. J Med Primatol. 2006;35(3):172-6. PubMed PMID: 16764676.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of efficacy of moxidectin and ivermectin in the treatment of Strongyloides fulleborni infection in rhesus macaques. AU - Dufour,Jason P, AU - Cogswell,Frank B, AU - Phillippi-Falkenstein,Kathrine M, AU - Bohm,Rudolf P, PY - 2006/6/13/pubmed PY - 2006/7/19/medline PY - 2006/6/13/entrez SP - 172 EP - 6 JF - Journal of medical primatology JO - J Med Primatol VL - 35 IS - 3 N2 - BACKGROUND: Strongyloides infection may result in clinical disease or confound experimental protocols that utilize non-human primates. There is presently a Strongyloides fulleborni infection rate of approximately 27% in the Tulane National Primate Research Center's breeding colonies despite the routine therapeutic and prophylactic use of ivermectin. METHODS: A study was conducted to determine if moxidectin treatment offers advantages to the intestinal parasite control program. A total of 150 rhesus macaques (Macaca mulatta) that were removed from the breeding colonies due to illness were selected for the study. The animals were randomly assigned to treatment groups with 75 receiving ivermectin and 75 receiving moxidectin. Egg counts were performed on fecal samples collected pre- and post-treatment. RESULTS: Both treatments resulted in decreases in the number of eggs/g in the post-treatment sample as compared with the pre-treatment sample; however, no significant difference was found between treatment groups. CONCLUSIONS: With the data demonstrating a similar efficacy in both ivermectin and moxidectin treated macaques, the benefit of moxidectin treatment relates to biosafety and topical application. SN - 0047-2565 UR - https://www.unboundmedicine.com/medline/citation/16764676/Comparison_of_efficacy_of_moxidectin_and_ivermectin_in_the_treatment_of_Strongyloides_fulleborni_infection_in_rhesus_macaques_ DB - PRIME DP - Unbound Medicine ER -